口腔疾病防治2024，Vol.32Issue(5)：359-366,8.DOI:10.12016/j.issn.2096-1456.2024.05.005
NLR对局晚期口腔鳞状细胞癌患者术前尼妥珠单抗联合新辅助化疗疗效预测价值研究
The value of NLR in predicting the efficacy of preoperative nimotuzumab combined with neoadjuvant chemo-therapy for local advanced oral squamous cell carcinoma
摘要
Abstract
Objective To investigate the value of the peripheral blood neutrophil to lymphocyte ratio(NLR)before nimotuzumab combined with neoadjuvant chemotherapy in predicting the short-term efficacy of neoadjuvant therapy for advanced oral squamous cell carcinoma(OSCC).Methods With the approval of the Ethics Committee and the in-formed consent of the patients,59 patients with stage Ⅲ and Ⅳ OSCC who were admitted to the Oral and Maxillofacial Surgery Department of the First Hospital of Shanxi Medical University from September 2020 to June 2023 were en-rolled.All the patients had complete clinical data,were pathologically diagnosed with squamous cell carcinoma,and re-ceived preoperative and received preoperative nimotuzumab+TP(docetaxel+cisplatin)neoadjuvant chemotherapy.The clinical data were analyzed,and the neutrophil and lymphocyte counts in peripheral blood were collected before and after nimotuzumab combined with neoadjuvant chemotherapy.The NLR was calculated,and the threshold value was calculated using the receiver operating characteristic(ROC)curve.Patients were divided into a high NLR group and a low NLR group according to the NLR threshold before nimotuzumab combined with neoadjuvant chemotherapy with TP.The clinical efficacy after nimotuzumab combined with neoadjuvant chemotherapy with TP was evaluated according to the evaluation criteria for solid tumor efficacy,and the correlation between the NLR and recent neoadjuvant therapy effi-cacy was analyzed.Immunohistochemical staining was used to detect the expression of epidermal growth factor receptor(EGFR)in OSCC tissues before and after nimotuzumab combined with neoadjuvant chemotherapy with TP and to ana-lyze whether the expression of EGFR differed among the different NLR groups.Results A total of 59 patients with ad-vanced OSCC were included.According to the ROC curve,the NLR threshold was 2.377,and the patients were divided into a＜2.377 group(low NLR group),with 24 patients,and a＞2.377 group(high NLR group),with 35 patients.The short-term neoadjuvant therapy effect was significantly greater in the lower NLR group than in the higher NLR group(P＜0.05);EGFR expression in both the low NLR group and the high NLR group decreased after nimotuzumab com-bined with neoadjuvant chemotherapy with TP,and the decrease in the low NLR group was significantly greater than that in the high NLR group(P＜0.05).Conclusion A low NLR before nimotuzumab combined with neoadjuvant che-motherapy with TP is associated with better neoadjuvant therapy outcomes,and such patients are more likely to benefit from preoperative nimotuzumab combined with neoadjuvant chemotherapy.关键词
中性粒细胞与淋巴细胞比值/口腔鳞状细胞癌/新辅助化疗/尼妥珠单抗/近期客观疗效/术前诱导化疗/表皮生长因子受体/化疗疗效/免疫组化Key words
neutrophil to lymphocyte ratio/oral squamous cell carcinoma/neoadjuvant chemotherapy/nimotu-zumab/short-term effects/preoperative induction chemotherapy/epithelial growth factor receptor/chemothera-peutic effects/immunohistochemistry分类
医药卫生引用本文复制引用
田亮亮,南欣荣..NLR对局晚期口腔鳞状细胞癌患者术前尼妥珠单抗联合新辅助化疗疗效预测价值研究[J].口腔疾病防治,2024,32(5):359-366,8.基金项目
This study was supported by the grants from Shanxi Province Natural Science Research Surface Project(202103021224413). 山西省自然科学研究面上项目(202103021224413) （202103021224413）
